 |
|
|
| |
Week 52 Subgroup Efficacy Analyses of Long-Acting Subcutaneous Lenacapavir in Phase 2/3 in Heavily Treatment-Experienced People With Multidrug-Resistant HIV (CAPELLA Study)
|
| |
| |
HIV Glasgow 2022, 23-26 Oct, Glasgow, UK
Antonella Castagna,1 José Luis Blanco,2 Chien-Ching Hung,3 Mohammed Rassool,4 Moti N. Ramgopal,5 William Sanchez,6 Catherine M. Cretico,7
Debbie Hagins,8 David A. Wheeler,9 Hui Wang,10 Ilana Henne,10 Hadas Dvory-Sobol,10 Martin S. Rhee,10 Jared Baeten,10 Onyema Ogbuagu11
1Università Vita-Salute San Raffaele, Milano, Italy; 2Hospital Clínic de Barcelona, Spain; 3National Taiwan University Hospital, Taipei City, Taiwan; 4Clinical HIV Research Unit, University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa; 5Midway Research Center, Fort Pierce, Florida, US;
6Floridian Clinical Research, Miami Lakes, Florida; 7Howard Brown Health, Chicago, Illinois, US; 8Coastal CARE Clinics, Chatham County Health Department, Savannah, Georgia, US; 9CARE-ID, Annandale, Virginia, US; 10Gilead Sciences, Inc., Foster City, California, US; 11Yale School of Medicine, New Haven, Connecticut, US
|
| |
|
|
|
|
|
